View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 3, 2017

Stealth begins SBT-20’s Phase I/II trial in Netherlands to treat Huntington’s disease

Stealth BioTherapeutics has begun the Phase I/II CHALLENGE-HD clinical trial of SBT-20 in the Netherlands to treat patients with early stage Huntington's disease.

Stealth BioTherapeutics has begun the Phase I/II CHALLENGE-HD clinical trial of SBT-20 in the Netherlands to treat patients with early stage Huntington's disease.

SBT-20 is an investigational tetrapeptide currently being developed to improve mitochondrial function for slowing down the neuronal degeneration and disease progression.

The two-part, randomised, double-blind, placebo-controlled Phase I/II trial is currently being conducted at the Centre for Human Drug Research (CHDR) and is designed to assess the safety, tolerability and efficacy of various doses of daily subcutaneous SBT-20 in adult patients.

The trial will enrol a total of 24 patients who will participate in both parts of the trial.

Stealth BioTherapeutics chief executive officer Reenie McCarthy said: "The initiation of CHALLENGE-HD is a significant milestone for Stealth as our second drug candidate enters human trials in a new therapeutic area.

"We plan to use the results from this trial to better inform our SBT-20 pipeline development plan and the broader potential of our platform in neurodegenerative disorders."

"As a leader in mitochondrial medicine, we want to pursue the full potential of mitochondria-targeted therapies, in rare primary mitochondrial diseases, common diseases of ageing and now in neurodegenerative disorders.

"We plan to use the results from this trial to better inform our SBT-20 pipeline development plan and the broader potential of our platform in neurodegenerative disorders."

The first part of the trial will include administration of one of three ascending doses of 5mg, 15mg and 25mg SBT-20 for seven days.

The data from this part of the trial will be used to choose a dose for administration in the second part for 28 days.

The primary endpoints of the trial are safety and tolerability, while the secondary endpoints include a measure of SBT-20's effect on mitochondrial, motor function and pharmacokinetic profile.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena